Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension safety study of macitentan in pulmonary arterial hypertension and validation of PAH-SYMPACT translations
2013-003489-15Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Long-term safety of macitentan. Started Nov 2013; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2013-003489-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003489-15.